WASHINGTON – U.S. Sen. Mark R. Warner (D-VA) released the following statement after Mylan announced it would reduce the cost of EpiPens for some consumers through a savings card:

“Like many Virginians, my own family relies on the EpiPen. While I’m glad public pressure has pushed Mylan to take a step in the right direction by expanding financial assistance for some families, it isn’t enough. I still am concerned about the underlying economics around EpiPen’s list price, which remains unchanged. Financial assistance programs can help some consumers but do nothing to lower costs for employers, insurers, taxpayer-funded programs like Medicare and Medicaid, and the many consumers who aren’t even eligible for discounts. I still have many unanswered questions and look forward to a timely and thoughtful response to the questions I laid out in my letter to Mylan earlier this week.”

###